Return to site

Gregor Diagnostics adds Zach Jeffery as Senior Advisor

Madison, WI. February 26, 2018. Gregor Diagnostics is excited to announce the addition of Zach Jeffery as a Senior Advisor. Mr. Jeffery has over 12 years of experience in the diagnostics space spanning sales and marketing, product development and management, and business unit leadership. As the former VP and General Manager of Urology at Miraca Life Sciences (fka Caris Life Sciences), Mr. Jeffery has launched products, partnerships, divisions, and net new businesses. He brings experience in developing and executing strategy, Healthcare M&A, market assessment, and specific experience in prostate cancer diagnostics and prognostics. He completed a BBA in Entrepreneurship and Real Estate from Wichita State University and an MBA from Texas Christian University.

“One of the key contributors to successful treatment of cancer is early detection. There are many companies chasing the holy grail of liquid biopsy, but Gregor’s approach is unique,” says Mr. Jeffery. “I believe their hypothesis of utilizing a specimen that contacts and is partially produced by the prostate has the potential to deliver on the promise of earlier and superior detection, disease stratification, and lower barriers to testing through a non-invasive collection process. I’m excited to be involved with Gregor Diagnostics and be a part of their journey to make a difference in men’s health”

As an experienced leader in prostate cancer diagnostics Mr. Jeffery will be a valuable resource for Gregor in our efforts to determine the health economics of our test, to determine a pathway for payor reimbursement, and to obtain a better understanding of how our regulatory path may affect commercialization. With his background in Urology we are thrilled that Mr. Jeffery sees the potential of Gregor Diagnostics to have a positive impact in men’s health across the US and globally.

“Zach’s experience in navigating the commercialization landscape for new prostate cancer diagnostics is extremely valuable for the success of Gregor’s screening test,” states Tobias Zutz, CEO of Gregor Diagnostics. “His insights into the market ensure we develop a test that will be readily utilized and reimbursed upon launch. Gregor is fortunate to have attracted such as experienced leader in prostate cancer diagnostics.”


Tobias Zutz, Gregor Diagnostics

(920) 901-4950

 About Gregor Diagnostics

Gregor Diagnostics Inc. ( is a molecular diagnostics startup company developing a groundbreaking new screening test for prostate cancer. Gregor Diagnostics’ patient-friendly test will be the first diagnostic to detect prostate cancer at the earliest stages of the disease and differentiate between indolent and aggressive cancer. This will result in decreased overdiagnosis and overtreatment of indolent prostate cancer and more effective detection and management of aggressive prostate cancer.

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!